NeuTrace develops AI and machine learning-based diagnostic tools for the early detection and management of heart disease. The company's technology enhances the accuracy of cardiovascular assessments, enabling timely interventions and improved patient outcomes.
Funding
$4.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cardiovascular disease remains a leading cause of mortality, often due to late detection and intervention. Current diagnostic methods can be inaccurate or require invasive procedures, leading to delayed treatment and poorer patient outcomes.
Solution
NeuTrace is developing AI-powered diagnostic tools to improve the early detection and management of heart disease. Their technology leverages machine learning algorithms to analyze patient data and enhance the accuracy of cardiovascular assessments. By providing more precise and timely diagnoses, NeuTrace aims to enable earlier interventions, personalized treatment plans, and ultimately, improved patient outcomes in the fight against heart disease.
Target Audience
The primary target audience includes cardiologists, primary care physicians, and hospitals seeking advanced diagnostic tools for early and accurate detection of heart disease.
Features
- AI-driven analysis of patient data for enhanced cardiovascular risk assessment
- Machine learning models to improve the accuracy of diagnostic tests
- Non-invasive diagnostic tools for early detection of heart disease
- Predictive analytics to identify patients at high risk of cardiovascular events